Recent developments in the field include an evolving treatment landscape and the development of evidence-based guidelines.

AbbVie executives said they have high hopes for Skyrizi and Rinvoq in the inflammatory bowel disease market after Humira ...

Skyrizi had an estimated national TV ad spend of $367.7 million — the highest ad spend of any brand in the top 10.

Skyrizi is used to treat certain inflammatory conditions, such as plaque psoriasis. The drug starts working after your first dose. Skyrizi is approved by the Food and Drug Administration (FDA ...

President-elect Donald Trump’s administration is expected to push to ban TV advertising for prescription drugs — but Big ...

AbbVie closed out the year on a high note, as its blockbuster biologic Skyrizi once again claimed the top spot in 2024’s ...

The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second ...

High-yield dividend stocks may not appeal to some investors. However, if you're among those investors looking for income, ...

AbbVie executives say the company’s immunology drugs Skyrizi and Rinvoq are expanding their reach in the inflammatory bowel disease (IBD) as the market for Humira biosimilars heats up.